Higher Dispositional Optimism Predicts Better Health-Related Quality of Life After Esophageal Cancer Surgery: A Nationwide Population-Based Longitudinal Study

This Swedish nationwide longitudinal research included 192 sufferers who underwent esophagectomy for most cancers. The publicity was dispositional optimism measured by the Life Orientation Check-Revised (LOT-R) at 1 yr post-surgery. Sufferers have been categorized into 4 subgroups (very low, reasonably low, reasonably excessive, and really excessive dispositional optimism) primarily based on the quartile of the LOT-R sum rating. The result was HRQL assessed by the European Group for Analysis and Therapy of Most cancers High quality of Life Questionnaire-Core 30 and High quality of Life Questionnaire-Esophago-Gastric module 25 at 1, 1.5, and a couple of years post-surgery.

Linear mixed-effects fashions, adjusted for potential confounders, have been used to look at the imply rating distinction (MSD) with 95% confidence interval of HRQL among the many 4 affected person subgroups. Sufferers with very excessive dispositional optimism reported clinically relevantly higher world high quality of life, emotional perform, and social perform (MSD vary 10-16) and fewer extreme signs in ache, dyspnea, diarrhea, consuming problem, anxiousness, dry mouth, bother with style, fear about weight reduction, and self-doubt about physique picture (MSD vary – 9 to – 22) than sufferers with decrease dispositional optimism.

Sufferers with reasonably excessive dispositional optimism reported clinically and statistically considerably higher world high quality of life (MSD 10) and fewer extreme diarrhea (MSD – 9) than sufferers with decrease dispositional optimism. Adjusted MSDs have been fixed over the three time factors in all features aside from consuming problem. Subsequently, the DF-based SA successfully solves the issue of fabric shedding and growing older, thus enhancing the soundness and injury threshold of the fiber laser.

COVID-19: unbalanced administration of occupational risks-case of the evaluation of the chemical threat associated to the usage of disinfectants within the dairy business in Morocco

Moroccan employers have a robust duty for the security and well being of their staff within the office and for shielding them from the chance of COVID-19 and any occupational hazards, as required by Moroccan legislation. As a consequence, industries, together with the agri-food sector, have put in place preventive measures to cope with this pandemic on a number of fronts, together with the usage of hydroalcoholic merchandise and bleach for private and floor disinfection.

These disinfection actions might remove or scale back the chance of coronavirus an infection, however the elevated use of those merchandise by staff may result in critical well being issues and improve the occupational chemical threat within the occasion of uncontrolled publicity. With the intention to analyze this threat within the dairy business in Morocco, we now have launched a qualitative and quantitative research to establish and assess the severity of chemical threat to which its staff are uncovered.

This includes an evaluation of the security information sheets [MSDS] of the disinfectants used and a well being and security survey of the customers of those merchandise, significantly for hand disinfection. This evaluation confirmed that this chemical threat is omnipresent and prevention measures are partially adopted. Certainly, the strengthening of well being security measures to fight COVID-19 has considerably elevated this threat, leading to a outstanding imbalance within the evaluation and administration of occupational dangers on this business.

That is the usage of the Danger Evaluation-Important Management Factors (HACCP)-Instrument for a First Danger Evaluation by Exercise Evaluation (OPERA) method, which we developed and proposed in a earlier research, for a simplified administration of chemical threat within the meals business, particularly in small- and medium-sized enterprises. These outcomes have led us to suggest corrective and preventive measures towards this threat to events and to undertake an built-in administration of meals and occupational well being dangers in a single system.

Higher Dispositional Optimism Predicts Better Health-Related Quality of Life After Esophageal Cancer Surgery: A Nationwide Population-Based Longitudinal Study

Monitoring-based deep studying methodology for temporomandibular joint segmentation

The form, measurement, and floor info regarding the glenoid fossae and condyles in temporomandibular joints (TMJ) are important for diagnosing and treating. Sufferers with TMJ illness usually have floor abrasion which can trigger fuzzy edges in computed tomography (CT) imaging, particularly for low-dose CT, making TMJ segmentation harder.  On this paper, an computerized segmentation algorithm primarily based on deep studying and post-processing was launched.
First, U-Internet was used to divide photos into three classes: glenoid fossae, condyles, and background. For structural fractures in these divided photos, the inner pressure constraint of a snake mannequin was used to replenish the integrity of the fracture boundary in a post-processing operation, and the preliminary boundary of the snake was obtained primarily based on the idea of the monitoring idea. A complete of 206 instances of low-dose CT have been used to confirm the effectiveness of the algorithm, and such indicators because the Cube coefficient (DC) and imply floor distance (MSD) have been used to judge the settlement between experimental outcomes and the gold normal.

Anti-CD19-ScFv-4-1BB-CD3ζ (Bsd)

LVP1441 1x10^8 IFU/ml x 200ul
EUR 455
Description: Anti-CD19 CAR Lentivirus with human 4-1BB (CD137) stimulatory domain, containing Blasticidin selection

Anti-CD19-ScFv-4-1BB-CD3ζ (Puro)

LVP1440 1x10^8 IFU/ml x 200ul
EUR 455
Description: Anti-CD19 CAR Lentivirus with human 4-1BB (CD137) stimulatory domain, containing Puromycin selection.

Anti-CD19-ScFv-4-1BB-CD3ζ (no marker)

LVP1444 1x10^8 IFU/ml x 200ul
EUR 455
Description: Anti-CD19 CAR Lentivirus with human 4-1BB (CD137) stimulatory domain, do not contain any selection marker.

Anti-CD19-ScFv-4-1BB-CD3ζ (GFP-Puro)

LVP1442 1x10^8 IFU/ml x 200ul
EUR 455
Description: Anti-CD19 CAR Lentivirus with human 4-1BB (CD137) stimulatory domain, containing GFP-Puromycin dual selection.

Anti-CD19-ScFv-4-1BB-CD3ζ (RFP-Puro)

LVP1443 1x10^8 IFU/ml x 200ul
EUR 455
Description: Anti-CD19 CAR Lentivirus with human 4-1BB (CD137) stimulatory domain, containing RFP-Puromycin dual selection.

CAR negative control: Anti-CD19-ScFv-4-1BB (Puro)

CAR-ctr2 1x10^8 IFU/ml x 200ul
EUR 276.5
Description: Anti-CD19 (4-1BB) control lentivirus without activation domain, containing Puromycin selection

Anti-CD19_CD20-ScFv- CD28-CD3ζ (Puro) Lentivirus

LVP1645 1x10^8 IFU/ml x 200ul
EUR 553
Description: Bispecific Anti-CD19/CD20 CAR Lentivirus with human CD28 stimulatory domain, containing puromycin antibiotic selection

Anti-CD19_CD20-ScFv- CD28-CD3ζ (No Select) Lentivirus

LVP1644 1x10^8 IFU/ml x 200ul
EUR 553
Description: Bispecific Anti-CD19/CD20 CAR Lentivirus with human CD28 stimulatory domain, do not contain antibiotic selection

Anti-CD19_CD20-ScFv- CD28-CD3ζ (GFP-Puro) Lentivirus

LVP1646 1x10^8 IFU/ml x 200ul
EUR 553
Description: Bispecific Anti-CD19/CD20 CAR Lentivirus with human CD28 stimulatory domain, containing GFP-Puromycin dual selection

Anti-CD19 CAR / NFAT (Luciferase) Reporter Jurkat Cell Line (CD19 SCFV-CD28-4-1BB-CD3ζ)

79853 2 vials
EUR 10340
Description: Anti-CD19 CAR/NFAT-luciferase reporter Jurkat cell line is a double stable cell line expressing anti-CD19 CAR and NFAT-luciferase reporter. It is made from the anti-CD19 CAR lentivirus (BPS Bioscience #79851). The reporter cell line has been validated for anti CD19-CAR expression by FACS, and for luciferase reporter activation stimulated by target cells including CD19/CHO recombinant cell line can be used for primary screening and functional validation of anti-CD19 CAR construct and lentivirus before testing in primary T cells.

Anti-CD19 CAR consists of anti-CD19 scFv linked to 3rd generation CAR (Chimeric Antigen Receptor) containing CD28, 4-1BB co-stimulatory domains, and CD3ζ signaling domain.

Anti-CD19_CD20-ScFv-4-1BB-CD3ζ (Puro) Lentivirus

LVP1642 1x10^8 IFU/ml x 200ul
EUR 553
Description: Bispecific Anti-CD19/CD20 CAR Lentivirus with human 4-1BB (CD137) stimulatory domain, containing puromycin antibiotic selection

Anti-CD19_CD20-ScFv-4-1BB-CD3ζ (No Select) Lentivirus

LVP1641 1x10^8 IFU/ml x 200ul
EUR 553
Description: Bispecific Anti-CD19/CD20 CAR Lentivirus with human 4-1BB (CD137) stimulatory domain, do not contain antibiotic selection

Anti-CD19_CD20-ScFv-4-1BB-CD3ζ (GFP-Puro) Lentivirus

LVP1643 1x10^8 IFU/ml x 200ul
EUR 553
Description: Bispecific Anti-CD19/CD20 CAR Lentivirus with human 4-1BB (CD137) stimulatory domain, containing GFP-Puromycin dual selection

Anti-CD19 CAR Lentivirus (CD19 ScFv-CD8-4-1BB-CD3ζ)

78600 50 µl
EUR 1150
Description: The anti-CD19 CAR lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. These viruses constitutively express the ScFv portion of anti-CD19 (clone FMC63) linked to 2nd generation CAR (Chimeric Antigen Receptor) containing CD8 hinge, 4-1BB, and CD3ζ signaling domains. 

Anti-CD28 Antibody [CD28.2], PE-25Tests

QAB37-PE-25Tests 25Tests
EUR 169.2

Anti-CD28 Antibody [CD28.2], APC-25Tests

QAB37-APC-25Tests 25Tests
EUR 188.4

Anti-CD28 Antibody [CD28.2], PE-100Tests

QAB37-PE-100Tests 100Tests
EUR 270

Anti-CD28 Antibody [CD28.2], APC-100Tests

QAB37-APC-100Tests 100Tests
EUR 310.8

Anti-CD28 Antibody [CD28.2], FITC-25Tests

QAB37-F-25Tests 25Tests
EUR 157.2

Anti-CD28 Antibody [CD28.2], FITC-100Tests

QAB37-F-100Tests 100Tests
EUR 240

Anti-CD28 Antibody [CD28.2], Qfluor 630-100ug

QAB37-QF630-100ug 100ug
EUR 259.2

Anti-CD28 Antibody [CD28.2], Unconjugated-100ug

QAB37-100ug 100ug
EUR 169.2

Anti-CD19 CAR Lentivirus (CD19 ScFv-CD8-4-1BB-CD3ζ; SIN Vector)

78601 50 µl
EUR 1150
Description: The anti-CD19 CAR lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to infect almost all types of mammalian cells, including primary and non-dividing cells. These viruses transduce the ScFv portion of anti-CD19 (clone FMC63) linked to 2nd generation CAR (Chimeric Antigen Receptor) containing CD8 hinge and transmembrane domains, 4-1BB and CD3ζ signaling domains .Note: This product transduces the same construct as the anti-CD19 CAR Lentivirus (CD19 ScFv-CD8-4-1BB-CD3ζ) (BPS Bioscience #78600), but differs in key aspects:78601 is constructed with a SIN lentivector while 78600 is not. 78601 does not contain an antibiotic for selection while 78600 contains a puromycin selection so the transduced cells can be selected with puromycin.

Anti-CD28 Antibody [CD28.2], PE-Cy7-25Tests

QAB37-PE7-25Tests 25Tests
EUR 199.2

Anti-CD28 Antibody [CD28.2], PerCP-Cy5.5-100Tests

QAB37-PCP55-100Tests 100Tests
EUR 381.6

Anti-CD28 Antibody [CD28.2], PerCP-Cy5.5-25Tests

QAB37-PCP55-25Tests 25Tests
EUR 229.2

Anti-CD28 Antibody [CD28.2], PE-Cy7-100Tests

QAB37-PE7-100Tests 100Tests
EUR 340.8

Anti-CD3/CD28 stimulus for human PBMC

CT372 50 tests
EUR 141.6

Anti-CD19/CD22 Bispecific CAR Lentivirus (Clones FMC63/m971 ScFv-CD8-4-1BB-CD3ζ)

78609 50 µl
EUR 1095
Description: The anti-CD19/CD22 Bispecific CAR lentiviruses are replication incompetent, HIV-based, VSV-G-pseudotyped lentiviral particles that are ready to infect almost all types of mammalian cells, including primary and non-dividing cells. These viruses transduce the ScFv (single-chain variable fragments) of anti-CD19 (clone FMC63) and anti-CD22 (clone m971) linked to a 2nd generation CAR (Chimeric Antigen Receptor) containing CD8 hinge and transmembrane domains, and the 4-1BB and CD3ζ signaling domains.

CAR negative control: CD28-CD3ζ (Puro)

CAR-ctr3 1x10^8 IFU/ml x 200ul
EUR 276.5
Description: CAR-T CD28 control lentivirus without targeting domain, containing Puromycin selection

Anti-BCMA-ScFv- CD28-CD3ζ (Puro) Lentivirus

LVP1651 1x10^8 IFU/ml x 200ul
EUR 553
Description: Anti-BCMA CAR Lentivirus with human CD28 stimulatory domain, containing Puromycin antibiotic selection.

Anti-CD28

E40YR1618 1 mg
EUR 2960
Description: Available in various conjugation types.

anti-CD28

YF-PA10780 50 ug
EUR 435.6
Description: Mouse polyclonal to CD28

Hamster Anti CD28 Antibody

20-abx137056
  • Ask for price
  • Ask for price
  • 0.5 mg
  • 1 mg

Anti-h CD22-ScFv- CD28-CD3ζ (Puro) Lentivirus

LVP1663 1x10^8 IFU/ml x 200ul
EUR 553
Description: Anti-h CD22 CAR Lentivirus with human CD28 stimulatory domain, containing Puromycin antibiotic selection.

Absolute Mcell™ Anti-CD3/CD28 Antibody Magnetic Particles, 5.5 µm, DMF Filed, Sterile

WHM-AB23-095 2.5 mg
EUR 850

Anti-h HER2-ScFv- CD28-CD3ζ (Puro) Lentivirus

LVP1657 1x10^8 IFU/ml x 200ul
EUR 553
Description: Anti-h HER2 CAR Lentivirus with human CD28 stimulatory domain, containing Puromycin antibiotic selection.

Anti-h TGFb-ScFv- CD28-CD3ζ (Puro) Lentivirus

LVP1675 1x10^8 IFU/ml x 200ul
EUR 553
Description: Anti-h TGFb CAR Lentivirus with human CD28 stimulatory domain, containing Puromycin antibiotic selection.

Hamster Anti CD28 FITC Antibody

20-abx137135
  • Ask for price
  • Ask for price
  • 0.5 mg
  • 1 mg

Anti-BCMA-ScFv- CD28-CD3ζ (No Select) Lentivirus

LVP1650 1x10^8 IFU/ml x 200ul
EUR 553
Description: Anti-BCMA CAR Lentivirus with human CD28 stimulatory domain, does not contain any antibiotic selection.

Anti-BCMA-ScFv- CD28-CD3ζ (GFP-Puro) Lentivirus

LVP1652 1x10^8 IFU/ml x 200ul
EUR 553
Description: Anti-BCMA CAR Lentivirus with human CD28 stimulatory domain, containing GFP-Puromycin dual selection.

Anti-CD28 Antibody

ER2001-42 100ul
EUR 189
Description: CD28 (Cluster of Differentiation 28) is one of the proteins expressed on T cells that provide co-stimulatory signals required for T cell activation and survival. T cell stimulation through CD28 in addition to the T-cell receptor (TCR) can provide a potent signal for the production of various interleukins (IL-6 in particular). CD28 is the receptor for CD80 (B7.1) and CD86 (B7.2) proteins. When activated by Toll-like receptor ligands, the CD80 expression is upregulated in antigen-presenting cells (APCs). The CD86 expression on antigen-presenting cells is constitutive (expression is independent of environmental factors). CD28 is the only B7 receptor constitutively expressed on naive T cells. Association of the TCR of a naive T cell with MHC:antigen complex without CD28:B7 interaction results in a T cell that is anergic.

Anti-CD28 Antibody

E38A8582 100ug/100ul
EUR 225
Description: Available in various conjugation types.

Anti-CD28 Antibody

E38A8787 100ug/100ul
EUR 225
Description: Available in various conjugation types.

Anti-CD28 antibody

STJ119563 100 µl
EUR 332.4
Description: The protein encoded by this gene is essential for T-cell proliferation and survival, cytokine production, and T-helper type-2 development. Several alternatively spliced transcript variants encoding different isoforms have been found for this gene.

Anti-CD28 antibody

STJ96609 200 µl
EUR 236.4
Description: Rabbit polyclonal to CD28.

Anti-CD28 antibody

STJ16100044 100 µg
EUR 424.8

Anti-CD28 antibody

STJ72503 100 µg
EUR 430.8

Anti-CD28 Antibody

A00065 0.1mg
EUR 449
Description: Boster Bio Anti-CD28 Antibody (Catalog # A00065). Tested in ELISA, WB, IHC, IF applications. This antibody reacts with Human.

Anti-CD19 CAR negative control/ NFAT (Luciferase) Reporter Jurkat Cell Line (CD19 SCFV-CD28 transmembrane motif)

79854 2 vials
EUR 1650
Description: Anti-CD19 CAR negative control/NFAT-luciferase reporter Jurkat cell line is a double stable cell line expressing anti-CD19 CAR negative control and NFAT-luciferase reporter. The anti-CD19 CAR negative control consists of anti-CD19 scFv linked to the CD28 transmembrane motif without any intracellular signaling domains. The reporter cell line has been validated for anti- CD19 expression by FACS, while the stimulation by target cells including CD19/CHO recombinant cell line has not activated the luciferase reporter gene in this cell line. The cell line can be used for the negative control of anti-CD19 CAR/Jurkat-NFAT cell line (BPS Bioscience, #79853)._x000D_ _x000D_

Anti-h CD22-ScFv- CD28-CD3ζ (No Select) Lentivirus

LVP1662 1x10^8 IFU/ml x 200ul
EUR 553
Description: Anti-h CD22 CAR Lentivirus with human CD28 stimulatory domain, does not contain any antibiotic selection.

Anti-h CD22-ScFv- CD28-CD3ζ (GFP-Puro) Lentivirus

LVP1664 1x10^8 IFU/ml x 200ul
EUR 553
Description: Anti-h CD22 CAR Lentivirus with human CD28 stimulatory domain, containing GFP-Puromycin dual selection.

Hamster Anti CD28 Biotinylated Antibody

20-abx137134
  • Ask for price
  • Ask for price
  • 0.5 mg
  • 1 mg

Anti-h HLA-A2-ScFv- CD28-CD3ζ (Puro) Lentivirus

LVP1669 1x10^8 IFU/ml x 200ul
EUR 553
Description: Anti-h HLA-A2 CAR Lentivirus with human CD28 stimulatory domain, containing Puromycin antibiotic selection.

Anti-h HER2-ScFv- CD28-CD3ζ (No Select) Lentivirus

LVP1656 1x10^8 IFU/ml x 200ul
EUR 553
Description: Anti-h HER2 CAR Lentivirus with human CD28 stimulatory domain, does not contain any antibiotic selection.

Anti-h TGFb-ScFv- CD28-CD3ζ (No Select) Lentivirus

LVP1674 1x10^8 IFU/ml x 200ul
EUR 553
Description: Anti-h TGFb CAR Lentivirus with human CD28 stimulatory domain, does not contain any antibiotic selection.

Anti-h HER2-ScFv- CD28-CD3ζ (GFP-Puro) Lentivirus

LVP1658 1x10^8 IFU/ml x 200ul
EUR 553
Description: Anti-h HER2 CAR Lentivirus with human CD28 stimulatory domain, containing GFP-Puromycin dual selection.

Anti-h TGFb-ScFv- CD28-CD3ζ (GFP-Puro) Lentivirus

LVP1676 1x10^8 IFU/ml x 200ul
EUR 553
Description: Anti-h TGFb CAR Lentivirus with human CD28 stimulatory domain, containing GFP-Puromycin dual selection.

Goat Anti-CD28 Antibody

TA311351 100 µg Ask for price

Goat Anti-Cd28 Antibody

TA311383 100 µg Ask for price

Goat anti-CD28 Antibody

dAP-2339 50ug
EUR 264.6

Mouse anti-CD28 Antibody

DL99412A-100ul 100 ul
EUR 299
Description: T-cell-specific surface glycoprotein CD28; TP44; CD28

Mouse anti-CD28 Antibody

DL99412A-50ul 50 ul
EUR 210
Description: T-cell-specific surface glycoprotein CD28; TP44; CD28

Anti-Cd28 (mouse) antibody

STJ72504 100 µg
EUR 430.8

Anti-CD28 Agonist Antibody

100182-1 50 µg
EUR 335
Description: Recombinant monoclonal antibody recognizing human CD28. This antibody binds to CD28 on T cells and promotes T cell response. Not tested in other species. This antibody crosslinked with FcGR2B is useful for activation of CD27 costimulatory pathway in T cells.

Anti-CD28 Agonist Antibody

100182-2 100 µg
EUR 460
Description: Recombinant monoclonal antibody recognizing human CD28. This antibody binds to CD28 on T cells and promotes T cell response. Not tested in other species.

CAR negative control: CD28-CD3ζ (No Select) Lentivirus

CAR-ctr6 1x10^8 IFU/ml x 200ul
EUR 276.5
Description: CAR (CD28) control lentivirus without targeting domain, does not contain any antibiotic selection

CAR negative control: CD28-CD3ζ (GFP-Puro) Lentivirus

CAR-ctr8 1x10^8 IFU/ml x 200ul
EUR 276.5
Description: CAR (CD28) control lentivirus without targeting domain, containing GFP-Puromycin dual selection

Goat anti-Cd28 (mouse) Antibody

dAP-2313 50ug
EUR 264.6

Anti-CD28 Antibody Picoband™

A00065-3 10ug
EUR 154
Description: Western blot, 0.25-0.5 μg/ml, Human;_x000D_Flow Cytometry, 1-3 μg/1x106 cells, Human;_x000D_Direct ELISA, 0.1-0.5 μg/ml, Human

Anti-h HLA-A2-ScFv- CD28-CD3ζ (No Select) Lentivirus

LVP1668 1x10^8 IFU/ml x 200ul
EUR 553
Description: Anti-h HLA-A2 CAR Lentivirus with human CD28 stimulatory domain, does not contain any antibiotic selection.

Rabbit anti-CD28 (pY218) Antibody

DL90184A-100ul 100 ul
EUR 299
Description: T-cell-specific surface glycoprotein CD28; TP44; CD28

Rabbit anti-CD28 (pY218) Antibody

DL90184A-50ul 50 ul
EUR 209.3
Description: T-cell-specific surface glycoprotein CD28; TP44; CD28

Rabbit anti-CD28 (pY218) Antibody

YLD1497-100ul 100 ul
EUR 320
Description: Rabbit polyclonal antibody to CD28 (pY218)

Rabbit anti-CD28 (pY218) Antibody

YLD1497-50ul 50 ul
EUR 200
Description: Rabbit polyclonal antibody to CD28 (pY218)

Anti-h HLA-A2-ScFv- CD28-CD3ζ (GFP-Puro) Lentivirus

LVP1670 1x10^8 IFU/ml x 200ul
EUR 553
Description: Anti-h HLA-A2 CAR Lentivirus with human CD28 stimulatory domain, containing GFP-Puromycin dual selection.

Syrian Hamster anti-CD28 Antibody

DL99429A-100ul 100 ul
EUR 299
Description: T-cell-specific surface glycoprotein CD28; TP44; CD28

Syrian Hamster anti-CD28 Antibody

DL99429A-50ul 50 ul
EUR 210
Description: T-cell-specific surface glycoprotein CD28; TP44; CD28

Anti-CD30 / TNFRSF8 Antibody (CD30/412)

A1484-100 each
EUR 574.8

Anti-CD28 Reference Antibody (FR104)

E24CHA679 100 μg
EUR 225
Description: Available in various conjugation types.

Anti-CD28 Agonist Antibody (Humanized)

100186-1 50 µg
EUR 345
Description: Recombinant monoclonal antibody recognizing human CD28. This antibody binds to CD28 on T cells and promotes T cell response. Not tested in other species. This antibody crosslinked with FcGR2B is useful for activation of CD27 costimulatory pathway in T cells. This antibody has been humanized to reduce immunogenicity and improve the therapeutic half-life.

Anti-CD28 Agonist Antibody (Humanized)

100186-2 100 µg
EUR 475
Description: Recombinant monoclonal antibody recognizing human CD28. This antibody binds to CD28 on T cells and promotes T cell response. Not tested in other species. This antibody has been humanized to reduce immunogenicity and improve the therapeutic half-life.

Anti-CD16/CD32 Antibody

E38A8954 100ug/100ul
EUR 225
Description: Available in various conjugation types.

Anti-CD40/Cd40 Antibody

A00068-1 100ug/vial
EUR 352.8

Anti-CD16+CD32 antibody

MO16A(V100) 100 ug
EUR 60

Anti-CD16+CD32 antibody

MO16A(V25) 25 ug
EUR 60

Anti-CD16+CD32 antibody

MO16B(V100) 100 ug
EUR 60

Anti-CD16+CD32 antibody

MO16B(V25) 25 ug
EUR 60

Anti-CD16+CD32 antibody

MO16CFB(V100) 100 ug
EUR 60

Anti-CD16+CD32 antibody

MO16CFB(V25) 25 ug
EUR 60

Anti-CD16+CD32 antibody

MO16F(V100) 100 ug
EUR 60

Anti-CD16+CD32 antibody

MO16F(V25) 25 ug
EUR 60

Anti-CD16+CD32 antibody

MO16F(V500) 500 ug
EUR 60

Anti-CD16+CD32 antibody

MO16PE(V100) 100 ug
EUR 60

Anti-CD16+CD32 antibody

MO16PE(V25) 25 ug
EUR 60

Anti-CD16+CD32 antibody

MO16PP(V100) 100 ug
EUR 60

Anti-CD16+CD32 antibody

MO16PP(V25) 25 ug
EUR 60

Anti-CD16+CD32 antibody

MO16PP5.5(V100) 100 ug
EUR 60

Anti-CD16+CD32 antibody

MO16PP5.5(V25) 25 ug
EUR 60

Anti-CD16+CD32 antibody

MO16PU(V100) 100 ug
EUR 60

Anti-CD16+CD32 antibody

MO16PU(V500) 500 ug
EUR 60

Rat anti-CD16/CD32 Antibody

DL99452A-100ul 100 ul
EUR 299
Description: CD32; FCG2; IGFR2; Low affinity immunoglobulin gamma Fc region receptor II-b; IgG Fc receptor II-b; CDw32; Fc-gamma RII-b; Fc-gamma-RIIb; FcRII-b; CD32

Rat anti-CD16/CD32 Antibody

DL99452A-50ul 50 ul
EUR 210
Description: CD32; FCG2; IGFR2; Low affinity immunoglobulin gamma Fc region receptor II-b; IgG Fc receptor II-b; CDw32; Fc-gamma RII-b; Fc-gamma-RIIb; FcRII-b; CD32

Anti-CD59/Cd59a Antibody

A00914 100ug/vial
EUR 400.8

Anti-CD70/Cd27L Antibody

A02853 100ul
EUR 476.4
Description: Rabbit Polyclonal CD70/Cd27L Antibody. Validated in WB and tested in Human.

Anti-CD22 CAR Lentivirus (Clone m971 ScFv-CD8-4-1BB-CD3ζ)

78608 50 µl
EUR 1095
Description: The anti-CD22 CAR lentiviruses are replication incompetent, HIV-based, VSV-G-pseudotyped lentiviral particles that are ready to infect almost all types of mammalian cells, including primary and non-dividing cells. These viruses transduce the ScFv (single-chain variable fragment) of anti-CD22 (clone m971) linked to a 2nd generation CAR (Chimeric Antigen Receptor) containing CD8 hinge and transmembrane domains, and the 4-1BB and CD3ζ signaling domains (below).

Anti-CD40L/CD40LG Antibody

A01114-1 100ug/vial
EUR 352.8

Anti-CD40L/Cd40lg Antibody

A01114-2 100ug/vial
EUR 400.8

Anti-CD40L/CD40LG Antibody

A01114-3 100ug/vial
EUR 352.8

Anti-CD16/CD32, Rat IgG2b Antibody

A1106-200 each
EUR 874.8

Recombinant Anti-CD33 x Anti-CD16 x CD123 Trispecific Antibody (Single-chain Triplebody)

SCTB-104 200μg Ask for price
Description: A trispecific antibody that is expressed as a single chain with three scFv units, two distal binding sites for CD33 and CD123, a central site for CD16. This BsAb can retarget NK cells to tumor cells. It is designed for the research of Acute myeloid leukemia (AML) therapy.

Anti-EMMPRIN / CD147 Reference Antibody (Centocor anti-CD147)

E24CHA651 100 μg
EUR 225
Description: Available in various conjugation types.

Anti-OX2R / CD200R1 Reference Antibody (Janssen anti-CD200R1)

E24CHA149 100 μg
EUR 225
Description: Available in various conjugation types.

Anti-CD16/CD32, Rabbit IgG Antibody

A1107-200 each
EUR 874.8

Anti-CD28 (lumretuzumab)-MC-MMAF ADC

ADC-W-2278 1mg Ask for price
Description: This ADC product is comprised of an anti-CD28 monoclonal antibody conjugated via a MC linker to MMAF

Anti-CD28 (lumretuzumab)-SMCC-DM1 ADC

ADC-W-2276 1mg Ask for price
Description: This ADC product is comprised of an anti-CD28 monoclonal antibody conjugated via a SMCC linker to DM1

Anti-CD28 (lumretuzumab)-SPDB-DM4 ADC

ADC-W-2277 1mg Ask for price
Description: This ADC product is comprised of an anti-CD28 monoclonal antibody conjugated via a SPDB linker to DM4

Anti-CD44v4 Antibody (Clone CD44v4/1219)

A1526-100 each
EUR 574.8

Anti-CD44v6 Antibody (Clone CD44v6/1246)

A1527-100 each
EUR 574.8

Anti-CD44v9 Antibody (Clone CD44v9/1459)

A1528-100 each
EUR 574.8

Anti-CD3-ZETA / CD247 antibody

STJ73100 100 µg
EUR 430.8

Anti-CD20 CAR Lentivirus (Clone Leu-16 ScFv-CD8-4-1BB-CD3ζ)

78606 50 µl
EUR 1095
Description: The anti-CD20 CAR lentiviruses are replication incompetent, HIV-based, VSV-G-pseudotyped lentiviral particles that are ready to infect almost all types of mammalian cells, including primary and non-dividing cells. These viruses transduce the ScFv (single-chain variable fragment) of anti-CD20 (clone Leu-16) linked to a 2nd generation CAR (Chimeric Antigen Receptor) containing CD8 hinge and transmembrane domains, and the 4-1BB and CD3ζ signaling domains .

Anti-CD28 Antibody [37.51], Unconjugated-25ug

QAB99-25ug 25ug
EUR 138

Anti-CD28 Antibody [37.51], Unconjugated-100ug

QAB99-100ug 100ug
EUR 178.8

Anti-CD28 Antibody [37.51], Unconjugated-500ug

QAB99-500ug 500ug
EUR 279.6

Anti-CD28 Antibody [37.51], Qfluor 630-100ug

QAB99-QF630-100ug 100ug
EUR 270

Anti-CD28 Antibody [37.51], Qfluor 630-500ug

QAB99-QF630-500ug 500ug
EUR 372

Goat anti-CD3-ZETA / CD247 Antibody

dAP-3199 50ug
EUR 264.6

Anti-CD28 (lulizumab pegol)-MC-MMAF ADC

ADC-W-2332 1mg Ask for price
Description: This ADC product is comprised of an anti-CD28 Monovalent antibody conjugated via a MC linker to MMAF

resDetect™ Anti-CD28 Antibody ELISA Kit

CRS-A014 96tests
EUR 652.7
Description: Similar to CD3 antibody, CD28 antibodies also can be used to stimulate the proliferation and activation of T cells in CIK cell therapy. Under the cooperation of other cytokines, such as IL2 and IL1a, CIK cells with rapid proliferation, high tumoricidal activity, broad tumor killing spectrum and non-MHC-restricted tumor killing characteristics are generated,which has significant effects on the treatment of cancer, chronic leukemia, liver disease and neurological diseases. Obviously, It is necessary to control the residues of raw materials in the final cell therapy products.

Anti-CD30/ TNFRSF8 Antibody Clone CD30/412, Unconjugated-20ug

943-MSM1-P0 20ug
EUR 279.6

Anti-CD28 (lulizumab pegol)-SMCC-DM1 ADC

ADC-W-2330 1mg Ask for price
Description: This ADC product is comprised of an anti-CD28 Monovalent antibody conjugated via a SMCC linker to DM1

Anti-CD28 (lulizumab pegol)-SPDB-DM4 ADC

ADC-W-2331 1mg Ask for price
Description: This ADC product is comprised of an anti-CD28 Monovalent antibody conjugated via a SPDB linker to DM4

Anti-CD11c Monoclonal Antibody (CD11C-100/D2)

CTA-228-100ug 100ug Ask for price
Description: Mouse anti-CD11c monoclonal antibody (CD11C-100/D2) for WB, IP.

Anti-CD11c Monoclonal Antibody (CD11C-100/D2)

CTA-228-1mg 1mg Ask for price
Description: Mouse anti-CD11c monoclonal antibody (CD11C-100/D2) for WB, IP.

Anti-CD30/ TNFRSF8 Antibody Clone CD30/412, Unconjugated-100ug

943-MSM1-P1 100ug
EUR 513.6

Mouse monoclonal Anti-CD11C Clone CD11C-100/D2

TA353267L 500 µg Ask for price

Anti-CD28L / CD80 Reference Antibody (galiximab)

E24CHA680 100 μg
EUR 225
Description: Available in various conjugation types.

Rabbit Polyclonal Anti-CD3 zeta (CD247) Antibody

TA348011 100 µg Ask for price

Goat Anti-CD3-ZETA / CD247 Polyclonal Antibody

TA341382 100 µg Ask for price

Anti-CD68 Antibody Clone CD68/G2, Unconjugated-100ug

968-MSM5-P1 100ug
EUR 513.6

Anti-TNFRSF5 / CD40 Reference Antibody (Emory U. anti-CD40)

E24CHA741 100 μg
EUR 225
Description: Available in various conjugation types.

Anti-PTPRC / CD45 Reference Antibody (Novartis anti-CD45)

E24CHA929 100 μg
EUR 225
Description: Available in various conjugation types.

Anti-TNFRSF7 / CD27 Reference Antibody (Organon anti-CD27)

E24CHB002 100 μg
EUR 225
Description: Available in various conjugation types.

Anti-CD44v4 Antibody Clone CD44v4/1219, Unconjugated-20ug

960-MSM6-P0 20ug
EUR 279.6

Anti-CD44v6 Antibody Clone CD44v6/1246, Unconjugated-20ug

960-MSM7-P0 20ug
EUR 279.6

Anti-CD44v9 Antibody Clone CD44v9/1459, Unconjugated-20ug

960-MSM8-P0 20ug
EUR 279.6

Anti-CD28 (lumretuzumab)-MC-Vc-PAB-MMAE ADC

ADC-W-2279 1mg Ask for price
Description: This ADC product is comprised of an anti-CD28 monoclonal antibody conjugated via a MC-Vc linker to MMAE

Anti-CD28 (lumretuzumab)-MC-Vc-PAB-SN38 ADC

ADC-W-2280 1mg Ask for price
Description: This ADC product is comprised of an anti-CD28 monoclonal antibody conjugated via a MC-Vc-PAB linker to SN38

Anti-CD44v4 Antibody Clone CD44v4/1219, Unconjugated-100ug

960-MSM6-P1 100ug
EUR 513.6

Anti-CD44v6 Antibody Clone CD44v6/1246, Unconjugated-100ug

960-MSM7-P1 100ug
EUR 513.6

Anti-CD44v9 Antibody Clone CD44v9/1459, Unconjugated-100ug

960-MSM8-P1 100ug
EUR 513.6

Anti-CD44v4 Antibody Clone CD44v4/1700R, Unconjugated-20ug

960-RBM10-P0 20ug
EUR 279.6

Anti-CD44v4 Antibody Clone CD44v4/1700R, Unconjugated-100ug

960-RBM10-P1 100ug
EUR 513.6

Anti-CD23 (S52)

YF-MA12968 50 ug
EUR 435.6
Description: Mouse monoclonal to CD23

Anti-CD23 (S51)

YF-MA12969 200 ul
EUR 435.6
Description: Mouse monoclonal to CD23

Anti-CD35/CD21 Recombinant Monoclonal Antibody (7G6) (Rabbit IgGκ)

CTA-041-100ug 100ug Ask for price
Description: Mouse anti-CD35/CD21 recombinant monoclonal antibody (7G6) (Rabbit IgGκ) for Flow Cytometry, IHC (FS), IP, WB, FUNC.

Anti-CD35/CD21 Recombinant Monoclonal Antibody (7G6) (Rabbit IgGκ)

CTA-041-1mg 1mg Ask for price
Description: Mouse anti-CD35/CD21 recombinant monoclonal antibody (7G6) (Rabbit IgGκ) for Flow Cytometry, IHC (FS), IP, WB, FUNC.

Recombinant Mouse Anti-CD28 monoclonal antibody, clone D665

CABT-L1150 200ug
EUR 1164

Anti-CD28 (lulizumab pegol)-MC-Vc-PAB-MMAE ADC

ADC-W-2333 1mg Ask for price
Description: This ADC product is comprised of an anti-CD28 Monovalent antibody conjugated via a MC-Vc linker to MMAE

Anti-CD28 (lulizumab pegol)-MC-Vc-PAB-SN38 ADC

ADC-W-2334 1mg Ask for price
Description: This ADC product is comprised of an anti-CD28 Monovalent antibody conjugated via a MC-Vc-PAB linker to SN38

Polyclonal Goat Anti-CD3-ZETA / CD247 Antibody (internal region)

APG00963G 0.1mg
EUR 580.8
Description: A polyclonal antibody raised in Goat that recognizes and binds to Human Goat Anti-CD3-ZETA / CD247 (internal region). This antibody is tested and proven to work in the following applications:
Utility of the SA in erbium-doped fiber laser and steady passive Q-switched operation with a most pulse power of 430.47 nJ is realized. By adjusting the polarization state and pump energy, high-power mode-locked pulses are generated with a pulse period and output energy of 199 fs and 54.13 mW, respectively. Additional, bound-state soliton pulses are obtained with a pulse width of 312 fs and soliton interval of 1.26 ps for the primary time primarily based on MXene supplies. Furthermore, by utility of the SA in ytterbium-doped fiber lasers, a steady dissipative soliton mode-locked pulse is obtained with a pulse width of 23 ps. These outcomes point out that the DF-based buried Mo2C as a novel SA offers a dependable methodology for all-fiber and multifunctional high-power ultrafast laser.

Leave a Reply

Your email address will not be published. Required fields are marked *